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Summary
Sleep apnoea is associated with negative outcomes following general anaesthesia. Current recommendations
suggest using short-acting anaesthetic agents in preference to standard agents to reduce this risk, but there is
currently no evidence to support this. This randomised controlled triple-blind trial tested the hypothesis that a
combination of short-acting agents (desflurane-remifentanil) would reduce the postoperative impact of general
anaesthesia on sleep apnoea severity compared with standard agents (sevoflurane-fentanyl). Sixty patients
undergoing hip arthroplasty under general anaesthesia were randomised to anaesthesia with desflurane-
remifentanil or sevoflurane-fentanyl. Respiratory polygraphy was performed before surgery and on the first and
third postoperative nights. The primary outcome was the supine apnoea-hypopnoea index on the first
postoperative night. Secondary outcomes were the supine apnoea-hypopnoea index on the third
postoperative night, and the oxygen desaturation index on the first and third postoperative nights. Additional
outcomes included intravenous morphine equivalent consumption and pain scores on postoperative days 1, 2
and 3. Pre-operative sleep study datawere similar between groups.Mean (95%CI) values for the supine apnoea-
hypopnoea index on the first postoperative night were 18.9 (12.7–25.0) and 21.4 (14.2–28.7) events.h1,
respectively, in the short-acting and standard anaesthesia groups (p = 0.64). Corresponding values on the third
postoperative night were 28.1 (15.8–40.3) and 38.0 (18.3–57.6) events.h1 (p = 0.34). Secondary sleep- and
pain-related outcomes were generally similar in the two groups. In conclusion, short-acting anaesthetic agents
did not reduce the impact of general anaesthesia on sleep apnoea severity compared with standard agents.
These data should prompt an update of current recommendations.
.................................................................................................................................................................
Correspondence to: E. Albrecht
Email: eric.albrecht@chuv.ch
Accepted: 13 July 2020
Keywords: anaesthesia; hip arthroplasty; perioperativemedicine; sleep apnoea
Twitter: @DrEAlbrecht
Introduction
Obstructive sleep apnoea (OSA) is characterised by
intermittent and recurrent episodes of apnoea due to
partial or complete obstruction of the upper airway during
sleep following a reduction in pharyngeal muscle tone [1].
The prevalence of sleep apnoea is high; 49% of men and
23% of women aged > 40 years in a Swiss population-
based cohort [2], and the condition is an important public
health issue due to its association with hypertension [3];
metabolic syndrome [4]; acute coronary syndrome [5];
stroke [6]; and mortality [7, 8].
In patients with OSA, volatile anaesthetics and opioids
increase the incidence of upper airway obstruction
secondary to a reduction in pharyngeal muscle tone [9]. In
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addition, opioids aggravate the risk of prolonged apnoea
by decreasing central respiratory drive [10]. Therefore,
patients with OSA are at an increased risk of developing
respiratory and cardiovascular complications after general
anaesthesia [11–13].
Current recommendations for anaesthetic
management of patients with OSA suggest that short-acting
agents such as desflurane and remifentanil should be used
for general anaesthesia [14, 15]. These agents have been
shown to be associated with an improved recovery profile,
oxygen saturation and respiratory rate 2 h after surgery
compared with sevoflurane or alfentanil in patients without
OSA [16, 17]. Furthermore, morbidly obese patients who
received general anaesthesia with desflurane had earlier
extubation times, earlier verbal contact, and were more
awake on arrival at the recovery area, compared with
morbidly obese patients who received sevoflurane [18].
However, there is still uncertainty about the benefits of
short-acting anaesthetic agents in patients with OSA
because they have not yet been compared with standard
agents in a randomised controlled clinical trial.
This study was designed to test the hypothesis that a
combination of desflurane and remifentanil (short-acting
agents) would reduce the impact of general anaesthesia on
postoperative OSA severity compared with a combination
of sevoflurane and fentanyl (standard agents).
Methods
This randomised, triple-blind, parallel-group trial was
conducted at the University Hospital of Lausanne between
February 2016 and May 2018. Randomisation was
undertaken using a computer-generated randomisation
table in aggregates of 10. Assignments were concealed in a
sealed opaque envelope. The patients, nursing staff,
research team, the sleep technician and the sleep physician
were not aware of treatment allocation. The trial was
sponsored by the Swiss National Science Foundation. The
study was approved by the hospital ethical committee and
all patients providedwritten informed consent.
Patients were eligible for participation in the study if they
were aged between 18 and 85 years and scheduled to
undergo hip arthroplasty. Exclusion criteria included:
treatment of sleep apnoea with continuous positive airway
pressure; presence of severe respiratory or cardiovascular
disease; malignant hyperthermia; pre-operative consumption
of benzodiazepines; chronic use of opioids at a dosage of
30 mg.day1 or more morphine equivalents; and pregnancy.
On the day of surgery, patients were randomised to general
anaesthesia with desflurane and remifentanil (short-acting
group), or sevofluraneand fentanyl (standardgroup).
Anaesthesia was induced using intravenous propofol
1.5–2.0 mg.kg1 and either remifentanil 0.5 µg.kg1 (short-
acting) or fentanyl 1–2 lg.kg1 (standard), with tracheal
intubation facilitated by intravenous rocuronium
0.6 mg.kg1. Anaesthesia was maintained using desflurane
(short-acting) or sevoflurane (standard) in an air-oxygen
mixture at a concentration of 0.8–1.2 minimum alveolar
concentration (MAC) to achieve a bispectral index (Aspect
Medical Systems, Norwood, MA, USA) of between 40 and
60. Analgesia to manage increases in heart rate or blood
pressure of more than 20% above pre-operative values was
provided with an infusion of remifentanil 0.1 µg.kg1.min1
(short-acting) or 25 µg bolus doses of fentanyl (standard)
[19]. Positive pressure ventilation was initiated, and tidal
volume and rate adjusted to maintain EtCO2 between 4.7
and 5.3 kPa.
After prosthesis implantation, the surgical site was
infiltrated with 50 ml of ropivacaine 0.2%. As per routine
institutional practice, at the end of surgery all patients
received intravenous acetaminophen 1000 mg and
intravenous ketorolac 30 mg for multimodal analgesia and
intravenous ondansetron 4 mg for anti-emetic prophylaxis
[20, 21]. In case of residual neuromuscular blockade
(defined as a train-of-four ratio < 0.9), muscle relaxationwas
antagonised with neostigmine 50 lg.kg1 and
glycopyrrolate 5–10 lg.kg1 [22]. In Phase 1 recovery, pain
was assessed on a visual analogue scale with a range of 0–
10. A score of 4 or more or patient request for analgesia was
managed with morphine 2 mg every 10 min as needed.
After resumption of oral intake, patients received
acetaminophen 1000 mg every 6 h, ibuprofen 400 mg
every 6 h, and oxycodone 5 mg every 3 h as needed.
Ongoing anti-emetic medication included intravenous
ondansetron 4 mg as needed. Patients received oxygen at a
rate of 2–4 l.min1 in Phase 1 recovery, but not after transfer
to theward.
Sleep-related parameters and outcomes were
measured on the night before surgery (pre-operative
baseline) and on the first and third nights after surgery using
a portable respiratory polygraph recorder (Embletta,
ResMed, San Diego, CA, USA). This system, previously
validated against polysomnography [23], allows non-
invasive recording of nasal airflow via nasal cannula, oxygen
saturation using finger pulse oximetry, respiratory efforts
using thoracic and abdominal belts, and body position. All
recordings were scored by a specialised sleep technician,
supervised and reviewed by a sleep specialist, and both
were unaware of treatment allocation. Apnoea was defined
as breathing cessation lasting for 10 s or more, and
hypopnoea was defined as a fall of 30% or more in the
46 © 2020 TheAuthors.Anaesthesia published by JohnWiley & Sons Ltd on behalf of Association of Anaesthetists
Anaesthesia 2021, 76, 45–53 Albrecht et al. | General anaesthesia and obstructive sleep apnoea
respiratory flow signal associated with a 3% or greater drop
in oxygen saturation. The apnoea-hypopnoea index (AHI)
was defined as the number of apnoeic and hypopnoeic
events per hour of recording time, and the oxygen
desaturation index reflected the number of oxygen
desaturations of 3% or more per hour of recording time.
Central apnoea was defined as the presence of > 50% of
events without abdominal or thoracicmovements.
The primary outcomewas the AHI in the supine position
on the first postoperative night. Secondary sleep-related
outcomes were: supine AHI on the third postoperative
night; AHI; obstructive apnoea index; mixed apnoea index;
central apnoea index; hypopnoea index; oxygen
desaturation index; percentage of recording time with
oxygen saturation below 90%; and proportion of time in the
supine position on the first and third postoperative nights.
Secondary pain-related outcomes were: intravenous
morphine AHI equivalent consumption in the recovery area
and on postoperative days 1, 2 and 3; pain scores at rest on
arrival and at departure and on postoperative days 1, 2 and
3; rates of postoperative nausea and vomiting or pruritus on
postoperative days 1, 2 and 3; and satisfaction score (rated
on a visual analogue scale from0 to 10).
It was calculated that 22 patients were required in each
treatment group to detect a difference in supine AHI of 5
events.h1 with a standard deviation of 5, 90% power and a
two-sided alpha error of 0.05. Based on an estimated drop-
out rate of 30%, the recruitment target was set at 60 subjects
(30 per group). A between-group difference in AHI of 5
events.h1 was chosen because this has previously been
defined as clinically relevant [3, 24].
Statistical analysis was performed using SPSS
Statistics for Windows Version 25.0 (IBM, Armonk, NY,
USA). Categorical data were summarised as rates and
continuous data were summarised as mean with 95%CI.
Categorical data were compared using the Fisher’s exact
Figure 1 Study flowdiagram.
© 2020 The Authors.Anaesthesiapublished by JohnWiley & Sons Ltd on behalf of Association of Anaesthetists 47
Albrecht et al. | General anaesthesia and obstructive sleep apnoea Anaesthesia 2021, 76, 45–53
test or Pearson Chi-square test with Yates’ correction as
appropriate. Continuous independent variables were
analysed using general linear models, while categorical
and continuous repeated measurements were analysed
using generalised estimating equations according to
time, anaesthesia group, and interaction between time
and anaesthesia effects. When more than one
distribution fitted the model, the best was chosen based
on the lowest quasi-likelihood under independence
model criterion for generalised estimating equations and
lowest Akaike information criterion for general linear
models.
Briefly, generalised estimating equations are an
extension of general linear models to longitudinal or
clustered data, where observations are no longer
independent. The aim was to extend the general linear
models estimating equations to the multivariate setting by
replacing the vector of responses and the vector of means
by their corresponding multivariate counterparts and using
a matrix of weights. Generalised estimating equations take
into account the dependence of observations by specifying
a working correlation matrix [25]. This increases the
efficiency of the estimators of the parameters compared
with those arising under the assumption that repeated
observations from a subject are independent of one
another, as long as this assumption is true and the resulting
estimators remain consistent in the absence of missing data
[26]. This method uses all the available information without







Age; y 64 (15) 66 (10)
Men; n 17 (71%) 16 (64%)
Weight; kg 81 (71–93 [58–130]) 82 (69–90 [62–135])
Height; cm 174 (9) 170 (9)
BMI; kg.m2 27.1 (24.3–29.6 [19.5–41.0]) 27.0 (24.6–31.0 [22.1–43.9])
ESS score ≥ 11 4 (17%) 4 (17%)
ASAphysical status
1 6 (25%)* 0
2 12 (50%) 22 (88%)*
3 6 (25%) 3 (12%)
Durationof surgery;min 132 (106–162 [80–360]) 136 (112–165 [76–252])
Hip arthroplasty
Primary 12 (50%) 11 (44%)
Secondary 12 (50%) 14 (56%)
Comorbidities
Coronary artery disease 0 2 (8%)
Hypertension 10 (42%) 10 (40%)
Renal failure 0 2 (8%)
Diabetes 1 (4%) 1 (4%)
Hyperlipidaemia 2 (8%) 3 (12%)
Sleep apnoea scores
NoSAS score ≥ 8 16 (67%) 19 (79%)
STOP-BANGscore ≥ 3 22 (92%) 20 (83%)
Berlin score ≥ 2 13 (54%) 10 (42%)
Pre-operative AHI
< 5 events.h1 4 (17%) 3 (12%)
5–14.9 events.h1 10 (42%) 9 (36%)
15–29.9 events.h1 6 (25%) 9 (36%)
≥ 30 events.h1 4 (17%) 4 (16%)
AHI, apnoea-hypopnoea index; ESS, Epworth Sleepiness Scale.
*Observed frequency significantly different fromoverall frequency (adjusted residual > |2|).
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excluding any individual, even if they are missing data at
some time-points.
To assess the generalisability of our findings,
sensitivity analyses were performed on sub-groups of
patients with OSA (AHI ≥ 5 events.h1 or ≥ 15 event.h1)
or at high risk of OSA (NoSAS score ≥ 8, STOP-BANG
score ≥ 3, or Berlin score ≥ 2). Multiple comparisons (for
time or interaction effects) were performed using
Bonferroni’s post-hoc test.
Results
Sixty patients were recruited and 49 completed the study for
the primary outcome (Fig. 1). Twelve and 15 patients did
not perform the last polygraphy in the standard and short-
acting groups respectively (p = 0.48). Patient characteristics
were similar in the two treatment groups (Table 1) and
between those who did vs. did not complete the last
polygraphy (online Supporting Information, Table S1). Only
one patient in the standard agents group had central
apnoea (58%of all apnoea events were not accompanied by
thoracic or abdominal effort).
The supine AHI did not differ significantly between the
short-acting and standard groups at baseline, or on the first
or third night after surgery (Fig. 2). The other secondary
sleep-related outcomes were comparable between groups
(Table 2). Changes from pre-operative baseline to the first
postoperative night were similar in those who did vs. did not
complete the final polygraphy (online Supporting
Information, Table S2).
The generalised estimating equations model did not
show any significant interaction (p = 0.63) or group effect
(p = 0.43), whereas a time effect was present (p < 0.0001)
when analysing the three nights in all patients (Table 3). The
supine AHI was significantly lower on postoperative night 1
compared with the pre-operative baseline (p = 0.03) and
postoperative night 3 (p = 0.003). There was no significant
difference between pre-operative baseline and the third
postoperative night (p = 0.41) (Table 3).
Overall, the prevalence of severe OSA (defined as an
AHI > 30 events.h1) on the third postoperative night was
significantly higher than on the pre-operative night (OR
7.00, 95%CI 2.07–23.60; p < 0.0001). The prevalence of
severe OSA on the first postoperative night did not differ
significantly from the pre-operative baseline (OR 2.50, 95%
CI 0.86–7.31); p = 0.09). Sensitivity analyses showed that
the study findings were consistent across patient sub-
groups based on OSA definition and in patients at high risk
ofOSA.
Pain scores were similar between groups during the
course of the study (online Supporting Information,
Figure S1). Other pain-related outcomes did not differ
significantly between treatment groups (Table 4), apart
from intravenous morphine equivalent consumption in the
recovery area, which was significantly higher in the short-
acting group (Table 4).
Discussion
The results of this randomised controlled trial suggest that
short-acting anaesthetic agents do not reduce the impact of
general anaesthesia on OSA severity on the first and third
postoperative nights, compared with standard agents. In
that context, given that both desflurane and remifentanil are
expensive agents [27], desflurane releases more carbon
dioxide into the atmosphere than other inhaled
anaesthetics [28] and that remifentanil is associated with
secondary hyperalgesia [29], we suggest that current
recommendations for the use of short-acting anaesthetics in
patients withOSA should probably be revised. Furthermore,
our results do not support existing recommendations that
encourage monitoring of patients on the first postoperative
night only [14, 15]. Our data suggest that monitoring should
be continued up to at least the third postoperative night.
However, this may not be feasible given the expansion of
ambulatory surgery and overall reductions in length of
hospital stay. Therefore, a temporary prescription for
continuous positive airway pressure therapy or a mandibular
advancement device might represent satisfactory and cost-
effective alternative measures for postoperative
management of patientswithOSA [30].
There are a number of potential explanations for the
lack of difference seen between short-acting and standard
Figure 2 Change in the apnoea-hypopnoea index (AHI) in
the supine position over time (values are shown asmean
with 95%CI). PreOP, pre-operative; PON1, postoperative
night 1; PON3, postoperative night 3. Blue line, standard
agents; red line, short-acting agents.
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anaesthetic agents on OSA severity during the first
postoperative night in our study. Firstly, although
desflurane has lower blood: gas and oil: gas partition
coefficients than sevoflurane, reducing absorption from
the fat compartment and resulting in quicker induction and
emergence times, the improved recovery profile does not
appear to extend beyond a period of 15–30 min [18].
Therefore, differences in pharmacodynamics between
these agents may be too small to have an impact on
postoperative OSA severity. Secondly, administration of
intravenous morphine postoperatively could have
neutralised any potential beneficial effects of the short-
acting agents. Indeed, patients in the short-acting group
actually received more morphine in the recovery area
(mean difference of 6 mg). This phenomenon, known as
secondary hyperalgesia, is well known after remifentanil
administration and primarily occurs during the first two
postoperative hours [29, 31]. However, intravenous
administration of long-acting opioids after a painful
surgical procedure is consistent with standard postoperative
pain management [32, 33] and mirrors the daily practice of
the recovery area.
The decrease in supine AHI on the first postoperative
night compared with the pre-operative baseline seen in our
study might be due to greater time awake (which artificially
decreases the AHI on polygraphy recordings) or a
Table 2 Sleep study data. Values aremean (95%CI).
Standard agents Short-acting agents p value
Pre-operative baseline (n = 24) (n = 25)
AHI; events.h1 17.6 (11.0–24.1) 19.4 (11.7–27.1) 0.68
OAI; events.h1 4.1 (1.2–7.0) 4.7 (0–9.4) 0.68
CAI; events.h1 1.5 (0.1–2.9) 2.6 (1.3–3.9) 0.12
MAI; events.h1 8.3 (0.5–16.0) 10.8 (1.2–20.5) 0.42
HI; events.h1 10.8 (7.0–14.7) 10.5 (7.3–13.7) 0.86
ODI; events.h1 21.0 (13.6–28.3) 22.9 (15.7–30.1) 0.67
Mean SpO2;% 92.2 (91.0–93.3) 92.8 (92.1–93.5) 0.35
Timewith SpO2 < 90%;% 16.1 (4.5–27.6) 8.7 (2.1–15.3) 0.09
Supine time;% 52.6 (39.8–65.4) 53.5 (41.7–65.4) 0.92
Postoperative night 1 (n = 24) (n = 25)
AHI; events.h1 20.7 (13.4–28.0) 18.8 (12.7–25.0) 0.73
OAI; events.h1 4.4 (1.1–9.9) 1.9 (0.3–4.1) 0.06
CAI; events.h1 2.1 (0.2–4.4) 1.7 (0.6–2.8) 0.56
MAI; events.h1 5.4 (1.7–9.0) 2.9 (0.8–6.7) 0.37
HI; events.h1 13.4 (8.7–18.1) 14.7 (10.2–19.1) 0.67
ODI; events.h1 29.0 (19.8–381) 28.0 (20.3–35.7) 0.89
Mean SpO2;% 91.5 (90.4–92.7) 91.1 (89.6–92.5) 0.60
Timewith SpO2 < 90%;% 24.6 (11.6–37.5) 25.3 (10.1–40.5) 0.93
Supine time;% 93.7 (88.0–99.3) 98.4 (95.2–101.7) 0.16
Postoperative night 3 (n = 12) (n = 10)
AHI; events.h1 37.2 (17.8–56.6) 28.1 (15.8–40.3) 0.41
OAI; events.h1 15.2 (0.1–30.5) 7.9 (0.3–15.6) 0.16
CAI; events.h1 4.5 (0.7–8.4) 2.7 (0.2–5.2) 0.22
MAI; events.h1 28.3 (4.5–52.2) 7.8 (1.3–16.9) 0.05
HI; events.h1 13.6 (6.0–21.2) 16.2 (8.5–23.9) 0.58
ODI; events.h1 41.3 (20.0–62.6) 34.5 (20.9–48.1) 0.59
Mean SpO2;% 91.5 (89.7–93.3) 93.1 (91.3–95.0) 0.14
Timewith SpO2 < 90%;% 19.7 (2.1–37.3) 14.1 (3.4–31.5) 0.51
Supine time;% 97.7 (94.8–100.6) 100.0 (100.0–100.0) 0.10
AHI, apnoea-hypopnoea index; CAI, central apnoea index; HI, hypopnoea index; MAI, mixed apnoea index; OAI, obstructive apnoea
index;ODI, oxygendesaturation index.
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decreased proportion of rapid eye movement sleep [34]
(because respiratory events occur predominantly during
this phase). Subsequently, apnoeic and hypopnoeic events,
and the oxygen desaturation index all increased on the third
postoperative night compared with previous recordings,
potentially due to a rebound in the amount of rapid eye
movement sleep, as reported previously [35]. Unfortunately,
we cannot confirm this because sleep stage data are not
available from polygraphy. However, polygraphy data from
38 sleep apnoea patients showed that time in rapid eye
movement sleep was lowest on the first postoperative night
and increased up to the fifth postoperative night [34].
Therefore, it is possible that the negative impact of general
anaesthesia on OSA severity could increase further after the
third postoperative night.
The pre-operative AHI values of 17.6 and 19.4
events.h1 in the two groups in our study might seem high
for unselected patients, but are in line with the results of a
recent meta-analysis showing that the mean (95%CI) AHI
was 15.5 (12.9–18.2) events.h1 in a general population







n = 22 p value
SupineAHI; events.h1 26.7 (21.5–33.1) 20.1 (16.2–25.0)‡ 32.6 (24.6–43.4)¶ < 0.01
AHI; events.h1 18.5 (14.4–23.8) 19.7 (15.8–24.7) 32.3 (24.3–43.0)‡¶ < 0.01
OAI; events.h1 4.4 (2.5–7.7) 2.9 (1.3–6.4) 11.0 (6.1–19.7)¶ < 0.01
CAI; events.h1 2.0 (1.2–3.2) 1.9 (1.1–3.4) 3.5 (2.1–5.9) < 0.01
MAI; events.h1 1.4 (0.4–0.8) 0.7 (0.3–1.4) 2.2 (1.2–4.1)¶ < 0.01
HI; events.h1 10.6 (8.6–13.2) 14.0 (11.3–17.4) 14.9 (10.9–20.2) 0.09
ODI; events.h1 21.9 (17.6–27.2) 28.5 (23.5–34.6)‡ 37.7 (28.7–49.6)‡ < 0.01
Mean SpO2;% 92.5 (91.8–93.1) 91.3 (90.4–92.1)
‡ 92.3 (91.3–93.4) 0.01
Timewith SpO2 < 90%;% 11.8 (7.3–19.2) 24.9 (17.2–36.2)
‡ 16.7 (8.8–31.5) < 0.01
Supine time;% 53.1 (96.0–93.0) 96.0 (93.0–99.1)‡ 98.8 (97.6–100.1)‡ < 0.01
AHI, apnoea-hypopnoea index; CAI, central apnoea index; HI, hypopnoea index; MAI, mixed apnoea index; OAI, obstructive apnoea
index;ODI, oxygendesaturation index.
*Indicating a time effect.
‡p < 0.05 compared to pre-operative night.
¶p < 0.05 compared to postoperative night 1.
Table 4 Acute pain-related outcomes. Data aremean (95%CI) or number (proportion).
Standard agents Short-acting agents p value
Recovery area
i.v.morphine equivalent consumption;mg 7 (4–10) 13 (10–16) 0.02
Postoperative day 1
i.v.morphine equivalent consumption;mg 6 (0–11) 4 (2–6) 0.51
PONV 2/23 (9%) 1/23 (4%) 1.00
Pruritus 0/23 0/23 –
Postoperative day 2
i.v.morphine equivalent consumption;mg 12 (2–23) 8 (4–12) 0.30
PONV 4/24 (17%) 2/25 (8%) 0.42
Pruritus 1/24 (4%) 0/25 0.49
Postoperative day 3
i.v.morphine equivalent consumption;mg 10 (3–18) 6 (3–9) 0.19
PONV 6/24 (25%) 2/23 (9%) 0.25
Pruritus 0/24 2/23 (9%) 0.23
VAS satisfaction score 9.0 (8.6–9.4) 9.4 (9.0–9.7) 0.82
i.v., intravenous; PONV, postoperative nausea and vomiting; VAS, visual analogue scale score (from0–10).
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aged 65–79 years [36]. Moreover, rates of sleep apnoea in
our study (85% with an AHI of 5 events.h1 or more) and
those reported previously [12, 13] suggest that OSA is
highly prevalent in pre-operative populations. Therefore,
implementation of protocols to manage OSA patients
undergoing surgery would place a significant burden on
anaesthetic departments. Thus, recommendations based
on evidence rather than expert opinion are essential.
Furthermore, current inclusive respiratory event definitions
and highly sensitive nasal pressure sensors may artificially
elevate the AHI, as previously suggested by our group [37].
On that basis and given that some older studies were
performed between 2006 and 2010 [12], we also wonder
whether the current AHI threshold should be revised, as
previously suggested [38].
Further research is needed to determine which patients
are at increased postoperative risk based on different
definitions of OSA. For example, data from a recent
prospective study showed that only severe OSA (AHI > 30
events.h1) was significantly associated with a composite
cardiovascular event outcome [13]. Therefore, we believe
that not only the recommendations for OSA management
during anaesthesia, but also the AHI threshold above which
they are implemented should be revised.
Although rigorously designed to minimise bias, our
study has some limitations. Polygraphy does not record
total sleep time, meaning that differences in sleep quality
between recording nights may have contributed to the AHI
variations observed. We were aware of this limitation but
elected not to perform standard polysomnography with an
electroencephalogram because this would create more
distress for patients already under stress in a peri-operative
setting. Nevertheless, the polygraphy system we used has
been validated against polysomnography with a high
sensitivity and specificity [23], and therefore we do not
believe this represents a major limitation. In addition, early
discharge or withdrawal of consent reduced the number of
patients participating in the final assessment, although total
numbers were still sufficient based on sample size
calculation. Nevertheless, secondary sleep outcomes
should be considered as exploratory, requiring further
investigation. Finally, registration of the study was
performed after the inclusion of the first two patients, but we
do not believe that this short delay impacted the validity of
our results.
In conclusion, short-acting agents do not appear to
reduce the impact of general anaesthesia on OSA severity
compared with standard agents, suggesting that current
recommendations for use of these agents in patients with
OSA should be revised.
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Figure S1. Change in pain score over time (values are
shown as mean with 95%CI). The generalised estimating
equations model showed that there was no significant
interaction (p = 0.15), group effect (p = 0.43) or time effect
(p = 0.37). RA, Recovery are; POD, postoperative day.
Table S1. Baseline and clinical characteristics for
patients who completed the study vs. those who did not
have the final polygraphy. Data are mean (SD), median (IQR
[range]) or number (proportion) as appropriate.
Table S2. Differences in sleep study data for
postoperative night one vs. baseline in patients who
completed the study vs. those who did not have the final
polygraphy. Data aremean (95%CI).
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